ICU Medical, Inc.
HealthcareNASDAQ:ICUI · NASDAQ Global Select
-$0.66 today
Vol 0.26M · Avg 0.29M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
0.0%
avg 3.1%
ROIC
0.7%
avg 3.3%
ROA
0.0%
avg 3.1%
Analysis
ROIC is currently the strongest return metric at 0.7% versus its period average of 3.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Vivek Jain | Chief Executive Officer & Chairman of the Board | $1.95M | — | 54 | $0.00 | <0.01% |
Christian Voigtlander | Chief Operating Officer | $950,000.00 | — | 58 | $51,154.00 | 0.20% |
Brian Michael Bonnell | Chief Financial Officer & Treasurer | $902,500.00 | — | 52 | $76,097.00 | 0.30% |
Virginia Ruth Sanzone | Corporate Vice President, General Counsel, Secretary & Compliance Officer | $817,000.00 | — | 51 | $19,460.00 | 0.08% |
Daniel Woolson | President | $766,692.00 | — | 49 | $22,479.00 | 0.09% |
Olivia Barrall | Vice President of Human Resources | — | — | — | — | — |
Ben Sousa | Chief Information Officer | — | — | — | $6,044.00 | 0.02% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
4
$2.63M
Sells
6
$1.64M
Net Sentiment
+$989,645.53
Net buying
Most Active
Greenberg David C.
3 transactions
Analysis
Insiders reported 4 buys worth $2.63M and 6 sells worth $1.64M over the last 12 months. That adds up to net buying of $989,645.53. Greenberg David C. was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -0.8% | +9.8% (15yr)1 analysts |
| Revenue | N/A | N/A | +2.5% | +13.8% (15yr)1 analysts |
| Net Income | N/A | N/A | +2.9% | +12.9% (15yr)1 analysts |
| EBIT | N/A | N/A | +3.8% | +0.3% (15yr)1 analysts |
Analysis
Recent growth has been strongest in EBIT at +3.8% over three years. Forward estimates point to Revenue at +13.8% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Travere Therapeutics, Inc.
NASDAQ:TVTX
$4.84B
LivaNova PLC
NASDAQ:LIVN
$4.36B
Haemonetics Corporation
NYSE:HAE
$3.55B
Arcutis Biotherapeutics, Inc.
NASDAQ:ARQT
$3.05B
Heartflow, Inc. Common Stock
NASDAQ:HTFL
$2.87B
Tarsus Pharmaceuticals, Inc.
NASDAQ:TARS
$2.67B
Disc Medicine, Inc.
NASDAQ:IRON
$2.60B
Prestige Consumer Healthcare Inc.
NYSE:PBH
$2.27B
DENTSPLY SIRONA Inc.
NASDAQ:XRAY
$2.02B
Perrigo Company plc
NYSE:PRGO
$1.52B
Who manages ICUI?
ICU Medical, Inc. (ICUI) lists 7 active executives. The top listed executive is Brian Michael Bonnell, Chief Financial Officer & Treasurer.
Are ICUI insiders buying or selling?
Recent insider activity shows net selling of $35.67M.
Explore More
Continue the stock analysis
Jump to another research area for this company.